Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
2473 The University of Texas at San Antonio (144361)
Principal Investigator: Klose,Karl E
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 50,000
Exceeds $250,000 (Is it flagged?): No
Start and End Dates: 5/1/20 - 4/30/23
Restricted Research: YES
Academic Discipline: Biology
Department, Center, School, or Institute: SO TX CTR EMERG INFECT DISEASE
Title of Contract, Award, or Gift: CV19: vaccine development
Name of Granting or Contracting Agency/Entity:
Texas Biomedical Research Institute
Program Title: none
Note:
SAMs 1.1.1 The ongoing COVID19 pandemic is caused by the novel coronavirus SARSCOV2; it is believed that immunity to infection will be conferred by the generation of neutralizing antibodies against the SARSCOV2 spike protein, which will prevent cell entry and subsequent disease. Our established collaborative team in San Antonio has been developing a live attenuated vaccine (LAV) for biothreat agents over the past decade. The vaccine platform Fn-iglD, developed by Dr. Karl Klose at UTSA, exhibits high levels of safety and efficacy against pulmonary tularemia in three different animal models, including non-human primates (NHP). We will adapt this optimal LAV platform to express the SARSCOV2 spike protein (Fn iglD-S), and evaluate the antibodies induced in vaccinated animals to determine if they have neutralizing activity that could ameliorate COVID19 infection. The pre-existing expertise in our well-integrated team will provide the synergy to develop a novel vaccine to combat the COVID19 pandemic. Results of this proof-of-concept study will facilitate the submission of more complex nonhuman primate studies using the most appropriate NHP model being evaluated at TBRI.
Discussion: No discussion notes